Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28176437 | 0.84 | EPHX1 (0.43) | CES2CES1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL792325 | 0.84 | EPHX1 (0.43) | CES2CES1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL5443541 | 0.81 | CES2 (0.52) | CES2CES1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL3955263 | 0.81 | CES2 (0.52) | CES2CES1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL7714802 | 0.80 | CES2 (0.43) | CES2CES1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL2400052 | 0.80 | ALDH1A1 (0.50) | CES2CES1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL9483721 | 0.80 | CES2 (0.46) | CES2CES1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL10975907 | 0.80 | CES2 (0.46) | CES2CES1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL4813468 | 0.80 | CES2 (0.46) | CES2CES1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL3990546 | 0.80 | HPGD (0.53) | CES2CES1HDAC8HDAC6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118984825-A | Novel cooling agent and preparation containing same | 西姆莱斯股份公司 | 2024-11-19 | — | — | CN | claimed |
| EP-4452941-A1 | ACTIVE INGREDIENTS WITH SIALAGOGUE AND TINGLING/FIZZY EFFECT, AND PREPARATIONS CONTAINING SAME | Symrise AG (DE) | 2024-10-30 | — | — | EP | claimed |
| CN-116685575-A | Novel cooling substances and formulations containing these cooling substances | 西姆莱斯股份公司 | 2023-09-01 | — | — | CN | claimed |
| WO-2023117119-A1 | ACTIVE INGREDIENTS WITH SIALAGOGUE AND TINGLING/FIZZY EFFECT, AND PREPARATIONS CONTAINING SAME | SYMRISE AG (DE) | 2023-06-29 | — | — | WO | claimed |
| CN-118984825-A | Novel cooling agent and preparation containing same | 西姆莱斯股份公司 | 2024-11-19 | — | — | CN | disclosed |
| EP-4452941-A1 | ACTIVE INGREDIENTS WITH SIALAGOGUE AND TINGLING/FIZZY EFFECT, AND PREPARATIONS CONTAINING SAME | Symrise AG (DE) | 2024-10-30 | — | — | EP | disclosed |
| US-20240175022-A1 | RUNX1 Inhibition for Treatment of Proliferative Vitreoretinopathy and Conditions Associated with Epithelial to Mesenchymal Transition | MASSACHUSETTS EYE AND EAR INFIRMARY | 2024-05-30 | — | — | US | disclosed |
| CN-112384077-B | Solubilization of poorly soluble Cooling Material | 西姆莱斯有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20230406813-A1 | P62-ZZ CHEMICAL INHIBITOR | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2023-12-21 | — | — | US | disclosed |
| US-20230277454-A1 | NANO-EMULSION OF CBFß-RUNX1 INHIBITOR FOR OCULAR DRUG DELIVER | MASSACHUSETTS EYE AND EAR INFIRMARY | 2023-09-07 | — | — | US | disclosed |
| CN-116685575-A | Novel cooling substances and formulations containing these cooling substances | 西姆莱斯股份公司 | 2023-09-01 | — | — | CN | disclosed |
| US-11739326-B2 | RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2023-08-29 | — | — | US | disclosed |
| WO-2007014919-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007014925-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007014926-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
| WO-2006136562-A1 | HETEROCYCLYLAMINOALKYL SUBSTITUTED BENZIMIDAZOLES | TIBOTEC PHARMACEUTICALS LTD (IE) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006136563-A1 | 2-SUBSTITUTED BENZIMIDAZOLES | TIBOTEC PHARMACEUTICALS LTD (IE) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006136561-A1 | 1- ( 2-AMINO-3- (SUBSTITUTED ALKYL)-3H-BENZIMIDAZOIYLMETHYL) -3-SUBTITUTED-1,3-DIHYDRO-BENZOIMIDAZOL-2-ONES WITH ACTIVITY ON RESPIRATORY SYNCYTIAL VIRUS | TIBOTEC PHARMACEUTICALS LTD (IE) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006097534-A1 | 1,3-DIHYDRO-BENZIMIDAZOL-2-YLIDENE AMINES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARMACEUTICALS LTD (IE) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006072636-A2 | 1, 5, 6-SUBSTITUTED-2-OXO-3-CYANO-1, 6A-DIAZA-TETRAHYDRO-FLUORANTHENES AS ANTI-INFECTIVE AGENTS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240175022-A1 | RUNX1 Inhibition for Treatment of Proliferative Vitreoretinopathy and Conditions Associated with Epithelial to Mesenchymal Transition | RUNX1, CXCL12, MITF | CES2 4883/4885CES1 4754/4885HDAC8 1131/4885 |
| US-20230406813-A1 | P62-ZZ CHEMICAL INHIBITOR | SQSTM1, CTSZ, BECN1 | CES2 4839/4885CES1 3807/4885HDAC8 572/4885 |
| US-11739326-B2 | RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition | RUNX1, CXCL12, MITF | CES2 4883/4885CES1 4744/4885HDAC8 1145/4885 |
| US-20230277454-A1 | NANO-EMULSION OF CBFß-RUNX1 INHIBITOR FOR OCULAR DRUG DELIVER | RUNX1, CBFB, IKZF1 | CES2 4590/4885CES1 2961/4885HDAC8 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.